Drug-eluting stent safety: findings from preclinical studies

References

• Morice MC, Serruys PW, Sousa JE et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N. Engl. J. Med.346(23), 1773–1780 (2002).
   PubMed Web of Science ®Google Scholar
• Moses JW, Leon MB, Popma JJ et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N. Engl. J. Med.349(14), 1315–1323 (2003).
   PubMed Web of Science ®Google Scholar
• Stone GW, Ellis SG, Cox DA et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N. Engl. J. Med.350(3), 221–231 (2004).
   PubMed Web of Science ®Google Scholar
• Daemen J, Wenaweser P, Tsuchida K et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet369(9562), 667–678 (2007).
   PubMed Web of Science ®Google Scholar
• Mauri L, Normand SL. Studies of drug-eluting stents: to each his own? Circulation117(16), 2047–2050 (2008).
   PubMedGoogle Scholar
• Ramcharitar S, Hochadel M, Gaster AL, Onuma Y, Gitt A, Serruys PW. An insight into the current use of drug eluting stents in acute and elective percutaneous coronary intervention in Europe; a report on the EuroPCI Survey. Eurointervention3, 429–441 (2007).
   Google Scholar
• Beohar N, Davidson CJ, Kip KE et al. Outcomes and complications associated with off-label and untested use of drug-eluting stents. JAMA297(18), 1992–2000 (2007).
   PubMed Web of Science ®Google Scholar
• Farb A, Boam AB. Stent thrombosis redux – the FDA perspective. N. Engl. J. Med.356(10), 984–987 (2007).
   PubMed Web of Science ®Google Scholar
• Win HK, Caldera AE, Maresh K et al. Clinical outcomes and stent thrombosis following off-label use of drug-eluting stents. JAMA297(18), 2001–2009 (2007).
   PubMed Web of Science ®Google Scholar
• Marroquin OC, Selzer F, Mulukutla SR et al. A comparison of bare-metal and drug-eluting stents for off-label indications. N. Engl. J. Med.358(4), 342–352 (2008).
   PubMedGoogle Scholar
• Joner M, Finn AV, Farb A et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J. Am. Coll. Cardiol.48(1), 193–202 (2006).
   PubMed Web of Science ®Google Scholar
• Finn AV, Joner M, Nakazawa G et al. Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation115(18), 2435–2441 (2007).
   PubMed Web of Science ®Google Scholar
• Virmani R, Kolodgie FD, Farb A, Lafont A. Drug eluting stents: are human and animal studies comparable? Heart89(2), 133–138 (2003).
   PubMed Web of Science ®Google Scholar
• Clowes AW, Reidy MA, Clowes MM. Kinetics of cellular proliferation after arterial injury. I. Smooth muscle growth in the absence of endothelium. Lab Invest.49(3), 327–333 (1983).
   PubMed Web of Science ®Google Scholar
• Zempo N, Koyama N, Kenagy RD, Lea HJ, Clowes AW. Regulation of vascular smooth muscle cell migration and proliferation in vitro and in injured rat arteries by a synthetic matrix metalloproteinase inhibitor. Arterioscler. Thromb. Vasc. Biol.16(1), 28–33 (1996).
   PubMed Web of Science ®Google Scholar
• Sata M, Maejima Y, Adachi F et al. A mouse model of vascular injury that induces rapid onset of medial cell apoptosis followed by reproducible neointimal hyperplasia. J. Mol. Cell. Cardiol.32(11), 2097–2104 (2000).
   PubMed Web of Science ®Google Scholar
• Lindner V, Reidy MA. Expression of VEGF receptors in arteries after endothelial injury and lack of increased endothelial regrowth in response to VEGF. Arterioscler. Thromb. Vasc. Biol.16(11), 1399–1405 (1996).
   PubMedGoogle Scholar
• Carter AJ, Aggarwal M, Kopia GA et al. Long-term effects of polymer-based, slow-release, sirolimus-eluting stents in a porcine coronary model. Cardiovasc. Res.63(4), 617–624 (2004).
   PubMed Web of Science ®Google Scholar
• Kollum M, Kaiser S, Kinscherf R, Metz J, Kubler W, Hehrlein C. Apoptosis after stent implantation compared with balloon angioplasty in rabbits. Role of macrophages. Arterioscler. Thromb. Vasc. Biol.17(11), 2383–2388 (1997).
   PubMed Web of Science ®Google Scholar
• Suzuki T, Kopia G, Hayashi S et al. Stent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model. Circulation104(10), 1188–1193 (2001).
   PubMed Web of Science ®Google Scholar
• Drachman DE, Edelman ER, Seifert P et al. Neointimal thickening after stent delivery of paclitaxel: change in composition and arrest of growth over six months. J. Am. Coll. Cardiol.36(7), 2325–2332 (2000).
   PubMed Web of Science ®Google Scholar
• Aoki J, Abizaid AC, Serruys PW et al. Evaluation of four-year coronary artery response after sirolimus-eluting stent implantation using serial quantitative intravascular ultrasound and computer-assisted grayscale value analysis for plaque composition in event-free patients. J. Am. Coll. Cardiol.46(9), 1670–1676 (2005).
   PubMed Web of Science ®Google Scholar
• Aoki J, Colombo A, Dudek D et al. Peristent remodeling and neointimal suppression 2 years after polymer-based, paclitaxel-eluting stent implantation: insights from serial intravascular ultrasound analysis in the TAXUS II study. Circulation112(25), 3876–3883 (2005).
   PubMed Web of Science ®Google Scholar
• Morice MC, Serruys PW, Barragan P et al. Long-term clinical outcomes with sirolimus-eluting coronary stents: five-year results of the RAVEL trial. J. Am. Coll. Cardiol.50(14), 1299–1304 (2007).
   PubMed Web of Science ®Google Scholar
• Garcia-Touchard A, Burke SE, Toner JL, Cromack K, Schwartz RS. Zotarolimus-eluting stents reduce experimental coronary artery neointimal hyperplasia after 4 weeks. Eur. Heart J.27(8), 988–993 (2006).
   PubMedGoogle Scholar
• Collingwood R, Gibson L, Sedlik S, Virmani R, Carter AJ. Stent-based delivery of ABT-578 via a phosphorylcholine surface coating reduces neointimal formation in the porcine coronary model. Catheter Cardiovasc. Interv.65(2), 227–232 (2005).
   PubMed Web of Science ®Google Scholar
• Nakazawa G, Finn AV, John MC, Kolodgie FD, Virmani R. The significance of preclinical evaluation of sirolimus-, paclitaxel-, and zotarolimus-eluting stents. Am. J. Cardiol.100(8B), 36M–44M (2007).
   PubMed Web of Science ®Google Scholar
• Ahmed DD, Sobczak SC, Yunginger JW. Occupational allergies caused by latex. Immunol. Allergy Clin. North Am.23(2), 205–219 (2003).
   PubMedGoogle Scholar
• Leggat PA, Kedjarune U. Toxicity of methyl methacrylate in dentistry. Int. Dent. J.53(3), 126–131 (2003).
   PubMed Web of Science ®Google Scholar
• Wilson GJ, Nakazawa G, Schwartz RS et al. Comparison of inflammatory response following sirolimus and paclitaxel drug-eluting stents implanted in porcine coronary arteries. Circulation (2008) (In Press).
   Google Scholar
• Edelman ER, Rogers C. Pathobiologic responses to stenting. Am. J. Cardiol.81(7A), 4E–6E (1998).
   PubMed Web of Science ®Google Scholar
• Rogers C, Welt FG, Karnovsky MJ, Edelman ER. Monocyte recruitment and neointimal hyperplasia in rabbits. Coupled inhibitory effects of heparin. Arterioscler. Thromb. Vasc. Biol.16(10), 1312–1318 (1996).
   PubMed Web of Science ®Google Scholar
• Farb A, Heller PF, Shroff S et al. Pathological analysis of local delivery of paclitaxel via a polymer-coated stent. Circulation104(4), 473–479 (2001).
   PubMed Web of Science ®Google Scholar
• Heldman AW, Cheng L, Jenkins GM et al. Paclitaxel stent coating inhibits neointimal hyperplasia at 4 weeks in a porcine model of coronary restenosis. Circulation103(18), 2289–2295 (2001).
   PubMed Web of Science ®Google Scholar
• Kolodgie FD, John M, Khurana C et al. Sustained reduction of in-stent neointimal growth with the use of a novel systemic nanoparticle paclitaxel. Circulation106(10), 1195–1198 (2002).
   PubMed Web of Science ®Google Scholar
• Finn AV, Kolodgie FD, Harnek J et al. Differential response of delayed healing and persistent inflammation at sites of overlapping sirolimus- or paclitaxel-eluting stents. Circulation112(2), 270–278 (2005).
   PubMed Web of Science ®Google Scholar
• Joner M, Nakazawa G, Finn AV et al. Endothelial cell recovery between comparator polymer-based drug-eluting stents. J. Am. Coll. Cardiol.52(5), 333–342 (2008).
   PubMed Web of Science ®Google Scholar
• Rodgers GP, Minor ST, Robinson K et al. Adjuvant therapy for intracoronary stents. Investigations in atherosclerotic swine. Circulation82(2), 560–569 (1990).
   PubMed Web of Science ®Google Scholar
• Virmani R, Kolodgie FD, Burke AP, Farb A, Schwartz SM. Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler. Thromb. Vasc. Biol.20(5), 1262–1275 (2000).
   PubMed Web of Science ®Google Scholar
• Joner M, Farb A, Cheng Q et al. Pioglitazone inhibits in-stent restenosis in atherosclerotic rabbits by targeting transforming growth factor-β and MCP-1. Arterioscler. Thromb. Vasc. Biol.27(1), 182–189 (2007).
   PubMedGoogle Scholar
• Ribichini F, Joner M, Ferrero V et al. Effects of oral prednisone after stenting in a rabbit model of established atherosclerosis. J. Am. Coll. Cardiol.50(2), 176–185 (2007).
   PubMedGoogle Scholar
• Sakamoto J, Kimura H, Moriyama S et al. Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone. Biochem. Biophys. Res. Commun.278(3), 704–711 (2000).
   PubMed Web of Science ®Google Scholar
• Kwak BR, Mulhaupt F, Mach F. The role of PPARγ ligands as regulators of the immune response. Drug News Perspect.15(6), 325–332 (2002).
   PubMedGoogle Scholar
• Law RE, Goetze S, Xi XP et al. Expression and function of PPARγ in rat and human vascular smooth muscle cells. Circulation101(11), 1311–1318 (2000).
   PubMed Web of Science ®Google Scholar
• Schwartz RS, Edelman ER, Carter A et al. Drug-eluting stents in preclinical studies: recommended evaluation from a consensus group. Circulation106(14), 1867–1873 (2002).
   PubMed Web of Science ®Google Scholar
• Finn AV, Nakazawa G, Joner M et al. Vascular responses to drug eluting stents: importance of delayed healing. Arterioscler. Thromb. Vasc. Biol.27(7), 1500–1510 (2007).
   PubMed Web of Science ®Google Scholar
• Lüscher TF, Steffel J, Eberli FR et al. Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications. Circulation115(8), 1051–1058 (2007).
   PubMed Web of Science ®Google Scholar